Literature DB >> 26519331

Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes After Treatment With Empagliflozin.

Paris Roach1, Paul Skierczynski2.   

Abstract

Entities:  

Year:  2015        PMID： 26519331     DOI： 10.2337/dc15-1797

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  17 in total

1.  A Case of Euglycemic Diabetic Ketoacidosis Triggered by a Ketogenic Diet in a Patient With Type 2 Diabetes Using a Sodium-Glucose Cotransporter 2 Inhibitor.

Authors:  Paola Sanchez Garay; Gabriela Zuniga; Robert Lichtenberg
Journal:  Clin Diabetes       Date:  2020-04

2.  Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.

Authors:  Owais Rashid; Saad Farooq; Zareen Kiran; Najmul Islam
Journal:  BMJ Case Rep       Date:  2016-05-13

3.  Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.

Authors:  A Pfützner; D Klonoff; L Heinemann; N Ejskjaer; J Pickup
Journal:  Endocrine       Date:  2017-03-17       Impact factor: 3.633

4.  Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study.

Authors:  Louise Gek Huang Goh; Jiandong Sun; Benjamin Shao Kiat Ong; Daphne Khoo; Chee Fang Sum; Kwong Ng
Journal:  J Diabetes Metab Disord       Date:  2022-03-03

Review 5.  Options for empagliflozin in combination therapy in type 2 diabetes mellitus.

Authors:  Kenneth S Hershon
Journal:  Int J Gen Med       Date:  2016-05-25

Review 6.  Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.

Authors:  Jennifer M Trujillo; Wesley A Nuffer
Journal:  Pharmacotherapy       Date:  2017-02-24       Impact factor: 4.705

7.  A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis.

Authors:  Ashley M Zurek; Raghunandan Yendapally; Elizabeth M Urteaga
Journal:  Diabetes Spectr       Date:  2017-05

8.  Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.

Authors:  Labrini Papanastasiou; Spyridoula Glycofridi; Christos Gravvanis; Nikitas Skarakis; Irene Papadimitriou; Georgia Kanti; Chara Kapsali; Theodora Kounadi
Journal:  Hormones (Athens)       Date:  2020-11-05       Impact factor: 2.885

Review 9.  Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.

Authors:  James W Reed
Journal:  Vasc Health Risk Manag       Date:  2016-10-27

Review 10.  Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.

Authors:  Matthew J Levine
Journal:  Curr Diabetes Rev       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.